| BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia MS Zabriskie, CA Eide, SK Tantravahi, NA Vellore, J Estrada, FE Nicolini, ... Cancer Cell 26 (3), 428-442, 2014 | 344 | 2014 |
| A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer A Drilon, R Somwar, JP Wagner, NA Vellore, CA Eide, MS Zabriskie, ... Clinical Cancer Research 22 (10), 2351-2358, 2016 | 169 | 2016 |
| Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants CA Eide, MS Zabriskie, SLS Stevens, O Antelope, NA Vellore, H Than, ... Cancer cell 36 (4), 431-443. e5, 2019 | 164 | 2019 |
| Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia AM Eiring, BDG Page, IL Kraft, CC Mason, NA Vellore, D Resetca, ... Leukemia 31 (5), 1253-1254, 2017 | 157 | 2017 |
| Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia AM Eiring, BDG Page, IL Kraft, CC Mason, NA Vellore, D Resetca, ... Leukemia 29 (3), 586-597, 2015 | 143 | 2015 |
| PNAS Plus Significance Statements MA Davare, NA Vellore, JP Wagner, CA Eide, JR Goodman, A Drilon, ... PNAS 112 (39), 11997-11998, 2015 | 118* | 2015 |
| Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors MA Davare, NA Vellore, JP Wagner, CA Eide, JR Goodman, A Drilon, ... Proceedings of the National Academy of Sciences 112 (39), E5381-E5390, 2015 | 118 | 2015 |
| Protein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylase M Tortorici, MT Borrello, M Tardugno, LR Chiarelli, S Pilotto, G Ciossani, ... ACS chemical biology 8 (8), 1677-1682, 2013 | 80 | 2013 |
| Assessment of the Transferability of a Protein Force Field for the Simulation of Peptide-Surface Interactions NA Vellore, JA Yancey, G Collier, RA Latour, SJ Stuart Langmuir 26 (10), 7396-7404, 2010 | 80 | 2010 |
| LSD1/CoREST is an allosteric nanoscale clamp regulated by H3-histone-tail molecular recognition R Baron, NA Vellore Proceedings of the National Academy of Sciences 109 (31), 12509-12514, 2012 | 72 | 2012 |
| Comparison between empirical protein force fields for the simulation of the adsorption behavior of structured LK peptides on functionalized surfaces G Collier, N Vellore, J Yancey, S Stuart, R Latour Biointerphases 7 (1-4), 24, 2012 | 65 | 2012 |
| Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib W Qiang, O Antelope, MS Zabriskie, AD Pomicter, NA Vellore, P Szankasi, ... Leukemia, 2017 | 60 | 2017 |
| An improved replica-exchange sampling method: Temperature intervals with global energy reassignment X Li, CP O’Brien, G Collier, NA Vellore, F Wang, RA Latour, DA Bruce, ... The Journal of chemical physics 127, 164116, 2007 | 48 | 2007 |
| Molecular docking of bisphenol A and its nitrated and chlorinated metabolites onto human estrogen-related receptor-gamma S Babu, NA Vellore, AV Kasibotla, HJ Dwayne, MA Stubblefield, RM Uppu Biochemical and biophysical research communications 426 (2), 215-220, 2012 | 42 | 2012 |
| Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1 MS Zabriskie, NA Vellore, KC Gantz, MW Deininger, T O'Hare Leukemia 29 (9), 1939-1942, 2015 | 39 | 2015 |
| A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties HK Lee, L Zhang, MD Smith, A Walewska, NA Vellore, R Baron, ... Frontiers in pharmacology 6, 2015 | 39 | 2015 |
| SIRT5 is a druggable metabolic vulnerability in acute myeloid leukemia D Yan, A Franzini, AD Pomicter, BJ Halverson, O Antelope, CC Mason, ... Blood cancer discovery 2 (3), 266-287, 2021 | 38 | 2021 |
| Expanding the druggable space of the LSD1/CoREST epigenetic target: new potential binding regions for drug-like molecules, peptides, protein partners, and chromatin JC Robertson, NC Hurley, M Tortorici, G Ciossani, MT Borrello, ... PLoS Comput Biol 9 (7), e1003158, 2013 | 37 | 2013 |
| Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)‐Resistant CML Lines While Circumventing Pharmacokinetic Liabilities AM Ali, RF Gómez‐Biagi, DA Rosa, PS Lai, WL Heaton, JS Park, ... ChemMedChem 11 (8), 850-861, 2016 | 35 | 2016 |
| Simulation of multiphase systems utilizing independent force fields to control intraphase and interphase behavior PK Biswas, NA Vellore, JA Yancey, TG Kucukkal, G Collier, BR Brooks, ... Journal of Computational Chemistry 33 (16), 1458-1466, 2012 | 31 | 2012 |
Riccardo BaronThe University of UtahVerified email at utah.edu
